- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01627886
Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition
June 27, 2012 updated by: Dr. Reddy's Laboratories Limited
Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's Laboratories Limited, India and 'BONIVA®' 150 mg (Ibandronate Sodium) Tablets Of Roche Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions.
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, crossover, oral bioequivalence study.
Study Overview
Detailed Description
Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's Laboratories Limited, India And 'BONIVA®' 150 mg (Ibandronate Sodium)Tablets Of Roche Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions (With As Many Postmenopausal Women As Possible).
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 380 054
- BA Research India Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 64 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subjects should be healthy human of 18 years or older.
- The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
- The subjects should have a BMI between 19 and 30 weight in kg/ height2 in meter.
- The subjects should be able to communicate effectively with study personnel.
The subjects should be able to give written informed consent to participate in the study.
If subject is a female volunteer and
- Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms,foams, jellies, diaphragm, intrauterine device (IUD), or abstinence or
- Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject) or
- Should be postmenopausal healthy women who have attained complete menopause and have not had menstruation for at least one year and are not on hormone replacement therapy.
- Should have 17ß-estradiol serum levels of ≤92 pmol/L, follicle stimulating hormone (FSH) of ≥40 IU/L during the screening (only for postmenopausal healthy women)
Exclusion Criteria:
- The subjects who have a history of allergic responses to Ibandronate or other related drugs.
- The subjects who have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination, laboratory evaluations, ECG, X-ray and vaginal ultrasonography recordings (only for female subjects)]
- The subjects who have any disease or condition which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- The subjects who have a history or presence of bronchial asthma.
- The subject who have used enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
- The subjects who have history of drug dependence, recent history of alcoholism or of moderate alcohol uses.
- The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who can not refrain from smoking during study period.
- The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
- The subjects who have donated 1 unit (350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
- The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
- The subjects who have a positive test result for HIV antibody and / or syphilis (RPR/VDRL).
- The subject who receives an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.
- Female volunteers demonstrating a positive pregnancy screen.
- Female volunteers who are currently breast-feeding.
- Female volunteers not willing to use contraception during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ibandronate sodium tablets 150 mg
Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
|
Ibandronate sodium Tablets 150 mg
Other Names:
|
ACTIVE_COMPARATOR: Boniva
Boniva Tablets 150 mg of Roche Laboratories Inc, USA
|
Ibandronate sodium Tablets 150 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under curve(AUC)
Time Frame: Prior to dosing (0.0 hour) and at 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, 2.0, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0, 48.0 and 72.0 hours post dose.
|
Prior to dosing (0.0 hour) and at 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, 2.0, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0, 48.0 and 72.0 hours post dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dr. Simran Sethi, MBBS, BA Research India Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (ACTUAL)
September 1, 2008
Study Completion (ACTUAL)
October 1, 2008
Study Registration Dates
First Submitted
June 22, 2012
First Submitted That Met QC Criteria
June 25, 2012
First Posted (ESTIMATE)
June 26, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
June 28, 2012
Last Update Submitted That Met QC Criteria
June 27, 2012
Last Verified
November 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BA0859144-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Ibandronate sodium
-
Southwest Oncology GroupNational Cancer Institute (NCI)WithdrawnPain | Breast Cancer | Metastatic Cancer | Hypercalcemia of Malignancy
-
Cancer Research UKCompletedPain | Prostate Cancer | Metastatic CancerUnited Kingdom
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaboratorsCompleted
-
Wales Cancer Trials UnitVelindre NHS TrustUnknownBreast Cancer | Metastatic Cancer | Hypercalcemia of MalignancyUnited Kingdom
-
Liaoyang Central HospitalUnknown
-
German Breast GroupHoffmann-La Roche; AstraZenecaCompleted
-
Organon and CoCompletedPostmenopausal Osteoporosis
-
GlaxoSmithKlineCompleted
-
Hoffmann-La RocheCompletedPain; Bone Neoplasms; Neoplasm MetastasisBulgaria